venBio Partners
Venture capitalSan Francisco Β· SeedβLate Stage Β· 8 people tracked
Investment thesis
venBio invests in life sciences companies developing transformative medicines and technologies for unmet medical needs. The firm works closely with portfolio companies on intellectual property development, chemistry, manufacturing, and clinical trial strategy to optimize outcomes for both patient impact and acquisition readiness by potential industry partners.
Source: firm website, verified Jul 21, 2026.
Team Β· 8 people
from the firm's websiteWhat they invest in
from 13 of 73 portfolio companiesBiotech Γ13Healthtech Γ9Medical Devices Γ9AI & Machine Learning Γ3Deep Tech Γ2
HQs:United StatesΓ6AustraliaΓ1
Investments Β· showing 60 of 73
founders shown can be your intro pathAeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.
Biotech
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Richard Gaster(Director & Chairman)
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)in
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain. The company translates discoveries from Boston Children's Hospital, Harvard, and Laval University into first-in-class and best-in-class treatments.
BiotechMedical DevicesBoston, US
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.
BiotechHealthtech
Ken Song(Chairman, President and CEO)
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas. The company focuses on creating transformative treatments for patients in high-need therapeutic categories.
BiotechHealthtechMedical DevicesNew York, US
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.
BiotechHealthtechMedical Devices
Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories. The company serves biomedical researchers, pharmaceutical companies, and diagnostic labs with automated histology processing and pathology consultation.
AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US
Ke Cheng(Founder/CEO)inLinh Hoang(Chief Executive Officer)Jerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.
BiotechHealthtechMedical Devices
Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)
Regeneron discovers, develops, and manufactures biologics and genetic medicines for treating serious diseases including metabolic disorders, ophthalmology conditions, and rare diseases. The company serves patients globally through clinical trials and commercial pharmaceutical products.
BiotechHealthtechMedical DevicesTarrytown, US
Frequently asked questions
- What stage does venBio Partners invest at?
- venBio Partners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does venBio Partners focus on?
- venBio Partners focuses on Biotech, Medical Devices.
- Where is venBio Partners located?
- venBio Partners is headquartered in San Francisco, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.
A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.